Demographic analysis and outcome features in a transplant outpatient clinic

被引:6
作者
Kucuk, M
Sever, MS
Turkmen, A
Sahin, S
Kazancioglu, R
Ozturk, S
Eldegez, U
机构
[1] SSK Okmeydani Hosp, Istanbul, Turkey
[2] Istanbul Sch Med, Istanbul, Turkey
[3] SSK Goztepe Hosp, Istanbul, Turkey
[4] Haseki State Hosp, Istanbul, Turkey
关键词
D O I
10.1016/j.transproceed.2004.12.159
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Aim. This retrospective report analyzed the demographic features of kidney transplant outpatients grafted in Turkey and in different regions of the world. Methods. The patients were divided into 4 groups: 1. functional grafts (n = 432) 2. graft losses (n = 218) 3. deaths (n = 135) 4. lost to follow-up (n = 70) Every cohort was subgrouped as either receiving a cadaveric (CT) or a live donor transplant (LT) performed in our institute (ICT, n = 147, ILT, n = 304), other institutions in Turkey (TCT, n = 16, TLT, n = 86), or in a foreign country (FCT, n = 66, FLT, n 154). Results. Among the patients with functional grafts, FLT transplantations, of which the vast majority were paid transplantations, constituted the second largest group (n = 105) following ILT (n = 214). In the ILT group, 5- and 10-year graft survival rates were 76% and 50%, respectively, and patient survival rates were 88% and 78%, respectively. Considering the FLT group, 5- and 10-year graft survival figures were 70% and 42%, respectively, while patient survival rates in these periods were 81% and 69%, respectively. Patients with paid donor transplantations were characterized by a high risk of unconventional infectious complications in the early period, while midterm patient and graft survival was somewhat better than expected considering the high rate of complications in the early period. Conclusions. Paid organ transplantation should be discouraged. Organ donation should be stimulated by every means to avoid potentially fatal unconventional infections after transplantation from paid donors. If patients receive a paid transplant, however, they should be closely followed for these complications, since, if they survive the early period the midterm and long-term outcomes are quite reasonable.
引用
收藏
页码:743 / 746
页数:4
相关论文
共 22 条
[1]   Outcome after myocardial revascularization and renal transplantation - A 25-year single-institution experience [J].
Ferguson, ER ;
Hudson, SL ;
Diethelm, AG ;
Pacifico, AD ;
Dean, LS ;
Holman, WL .
ANNALS OF SURGERY, 1999, 230 (02) :232-241
[2]   A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND-STUDY OF TRIMETHOPRIM-SULFAMETHOXAZOLE FOR PROPHYLAXIS OF INFECTION IN RENAL-TRANSPLANTATION - CLINICAL EFFICACY, ABSORPTION OF TRIMETHOPRIM-SULFAMETHOXAZOLE, EFFECTS ON THE MICROFLORA, AND THE COST-BENEFIT OF PROPHYLAXIS [J].
FOX, BC ;
SOLLINGER, HW ;
BELZER, FO ;
MAKI, DG .
AMERICAN JOURNAL OF MEDICINE, 1990, 89 (03) :255-274
[3]  
GEFFNER SR, 1994, CLIN TRANSPL, V1995, P197
[4]   Living unrelated donor kidney transplantation [J].
Gjertson, DW ;
Cecka, JM .
KIDNEY INTERNATIONAL, 2000, 58 (02) :491-499
[5]   Living unrelated donors in kidney transplants - Better long-term results than with non-HLA-identical living related donors? [J].
Humar, A ;
Durand, B ;
Gillingham, K ;
Payne, WD ;
Sutherland, DE ;
Matas, AJ .
TRANSPLANTATION, 2000, 69 (09) :1942-1945
[6]   Double renal allografts successfully increase utilization of kidneys from older donors within a single organ procurement organization [J].
Johnson, LB ;
Kuo, PC ;
Schweitzer, EJ ;
Ratner, LE ;
Klassen, DK ;
HoehnSaric, EW ;
DelaTorre, A ;
Weir, MR ;
Strange, J ;
Bartlett, ST .
TRANSPLANTATION, 1996, 62 (11) :1581-1583
[7]   Living-unrelated renal transplantation provides comparable results to living-related renal transplantation: A 12-year single-center experience [J].
Lowell, JA ;
Brennan, DC ;
Shenoy, S ;
Hagerty, D ;
Miller, S ;
Ceriotti, C ;
Cole, B ;
Howard, TK .
SURGERY, 1996, 119 (05) :538-543
[8]   Payment for living donor (vendor) kidneys: A cost-effectiveness analysis [J].
Matas, AJ ;
Schnitzler, M .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (02) :216-221
[9]  
MATESANZ R, 2001, NEWSLETT TRANSPLANT, V6, P1
[10]  
*NIH, 1998, NIH PUBL, P3176